Biopharmaceutical Company Advances Potential Treatment for Fatal Tropical Disease and Autism Spectrum Disorder
PaxMedica (PXMD) has achieved a significant milestone with the completion of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement paves the way for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in Q4 2024, marking a crucial step towards the potential commercial availability of the first suramin form for the treatment of Stage 1 Human African Trypanosomiasis (HAT), a fatal tropical disease.
With PAX-101 already established as the standard treatment outside the United States for HAT, PaxMedica’s progress signifies a significant breakthrough in addressing neglected tropical diseases. Moreover, successful FDA approval could qualify the company for a Tropical Disease Priority Review Voucher (PRV), incentivizing further research and development in this critical area.
Howard Weisman, Chairman and CEO of PaxMedica, emphasized the company’s commitment to advancing treatments not only for HAT but also for Autism Spectrum Disorder. By ensuring a sustainable global supply chain for PAX-101, PaxMedica aims to expand its clinical investigations to explore the potential of suramin in treating the core symptoms of Autism Spectrum Disorder. This milestone underscores PaxMedica’s dedication to addressing some of the most challenging neurological conditions with innovative treatments.
Read original press release:here
You might like this article: Gold Hits Record High Amid Escalating Middle East Tensions
